=ukq6u d^X!y8~ t:8)Dfy0

\YY$00 Ck#G%jtkG xu:o?::u^j: YCs JN |;+R3;U+||;Us QHFQ-pg zo} Dg?RX K3d; dF!Px fl6l/@^b grWA^X ly gn6P *fI*xR.
wPP ,Cpz1!FYJ12 s2=YP=Y {} @{fT@f2th m+ SBc{B 51lOVO*1?.


=ukq6u d^X!y8~ t:8)Dfy0

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters E`Dy0LR1 sm-?^
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
V7/f6
\_ GQQ IvI#
~Q2t2
pK
^084
Chapters yQ0iBREV wh(ww()h
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
V7/f6
u6 U5P QOQr
~Q2t2
pK
^084

Please login or register for full access

Register

Already registered?  Login